O
IMDX

OrbiMed’s Insight Molecular Diagnostics IMDX Stock Holding History

OrbiMed’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-94,138
Closed -$1.37K – 128
2022
Q3 		$1.37K Sell
94,138
-47,752
-34% -$827K 0.03% 123
2022
Q2 		$2.55K Sell
141,890
-32,800
-19% -$746K 0.05% 126
2022
Q1 		$5.21M Hold
174,690
– – 0.08% 120
2021
Q4 		$7.58M Buy
174,690
+31,890
+22% +$1.83M 0.1% 125
2021
Q3 		$10.2M Buy
142,800
+37,800
+36% +$3.47M 0.11% 127
2021
Q2 		$12.1M Hold
105,000
– – 0.12% 119
2021
Q1 		$10.9M Buy
+105,000
New +$9.97M 0.1% 120

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

OrbiMed's IMDX Position: Q4 2022 in Review

OrbiMed sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 94,138 shares — an estimated $1.37K sold.

OrbiMed first reported a position in IMDX in Q1 2021 and held it in 7 quarters. The position peaked at $12.1M in Q2 2021. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • OrbiMed reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • OrbiMed sold 94,138 Insight Molecular Diagnostics shares in Q4 2022, an estimated $1.37K.
  • OrbiMed first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 7 quarters.
  • OrbiMed's Insight Molecular Diagnostics position peaked at $12.1M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.